March 09, 2010
Section : Research

The researchers exploring the “Schizophrenia and neurodevelopmental disorders” theme focus on the causes, course, treatment and prevention of: Schizophrenia and other psychotic disorders Attention deficit hyperactivity disorder (ADHD), conduct disorder, oppositional defiant disorder and Gilles de la Tourette syndrome Autism (research and evaluation) In Canada, one in a hundred people will be diagnosed with schizophrenia while 3 to 5% of children have an attention deficit...

March 09, 2010
Section : Research

The researchers working on the “Services, policy and population health” theme come from a wide variety of disciplinary backgrounds: psychiatry, epidemiology, law, anthropology, economy, psychology, social work, administration. Their goal is to inspire and influence developments in mental health policy so that people living with a mental illness can obtain the care and services to which they are entitled. To accomplish this, the researchers: Study the organization of mental health s...

July 02, 2014
Section : Social Media

Watch the 2013 Mini-Psych School's presentation of Valentina Munoz, Ph.D. on anxiety disorders.

November 20, 2012
Section : Social Media

The Eating Disorders Program and ANEB celebrate their 25th anniversary

June 19, 2012
Section : Social Media

Hitting bottom - Chronic or episodic depression and burnout? Watch this 2011 lecture by Dr. Mimi Israel (in French).

June 11, 2012
Section : Social Media

Volatile Emotions - Bipolar and other mood disorders. A 2011 lecture by Serge Beaulieu and Suzane Renaud (in French)

October 07, 2011
Section : Social Media

Creation of the Standard Life Centre for Breakthroughs in Teen Depression and Suicide Prevention

April 11, 2011
Section : Social Media

The Eating Disorder Mix: Genes, Environments and Gender - Video 2011

May 21, 2010
Section : Social Media

How Blue Is Blue? A 2009 lecture by Camillo Zacchia on depression - Part 2

November 06, 2009
Section : Social Media

A vaccine-based approach could be an effective therapy for people with mild or moderate form of Alzheimer's disease.